A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery (Q33371515)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

cardiac surgery

0 references

anticoagulation

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Shahid M Nimjee

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J R Keys

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G A Pitoc

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G Quick

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C P Rusconi

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bruce A Sullenger

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

9 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Molecular Therapy

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

408-415

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Cardiopulmonary bypass in humans: bypassing unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Direct effects of protamine sulfate on myocyte contractile processes. Cellular and molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Allergy to protamine sulfate

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Adverse events after protamine administration following cardiopulmonary bypass in infants and children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Inflammatory response to cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

RNA aptamers as reversible antagonists of coagulation factor IXa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Antidote-mediated control of an anticoagulant aptamer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Role of thrombin signalling in platelets in haemostasis and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Inflammation-coagulation network: are serine protease receptors the knot?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Inflammatory response to cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Negative inotropic effects of cytokines on the heart mediated by nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Mechanism of hepatocellular dysfunction during early sepsis. Key role of increased gene expression and release of proinflammatory cytokines tumor necrosis factor and interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Correlation between inflammatory response and markers of neuronal damage in coronary revascularization with and without cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Anaphylactoid reactions to protamine: an often lethal complication in insulin-dependent diabetic patients undergoing vascular surgery.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Identifiers

10.1016/J.YMTHE.2006.04.006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33371515&oldid=1979650424"